Hatteras Venture Partners related stories
All articles and analysis
Hatteras amasses $94 mln for sixth fundHatteras Venture Partners has raised $94 million for its sixth fund. The target is $200 million. The Durham, North Carolina-based venture firm makes seed and early-stage investments in health care.
- VC-backed StrideBio recruits Shah as CEO
Durham, North Carolina-based StrideBio Inc, a gene therapy company, has named Dr. Sapan Shah as CEO and a member of the company's board. Shah is a former chief executive at ARMGO Pharma and Ezose Sciences. StrideBio's backers include Hatteras Venture Partners, Takeda Ventures Inc, UCB Ventures and Alexandria Venture Investments LLC.
- Ribometrix scores $30 mln Series A
Durham, North Carolina-based Ribometrix, a biotechnology company, has closed $30 million in Series A financing. M Ventures led the round with participation from Amgen Ventures, Pappas Capital and Illumina Ventures. Founding investors SV Health Investors, AbbVie Ventures, Hatteras Venture Partners, MP Healthcare Venture Management, the Dementia Discovery Fund and Alexandria Venture Investments.
- Qpex Biopharma nabs $33 mln Series A
Qpex Biopharma, a developer of antiobiotics, has raised $33 million in Series A financing. New Enterprise Associates led the round with participation from Adams Street Partners, LYZZ Capital, Hatteras Venture Partners and Stanford University Draper Fund.
- VC-backed PhaseBio goes public
Pennsylvania-based PhaseBio Pharmaceuticals, a developer of treatments for orphan diseases, has raised $46 million for its IPO after pricing its 9.2 million shares at $5 per share. The stock began trading October 18, 2018 on the NASDAQ under the ticker symbol "PHAS." Citigroup, Cowen and Stifel are the lead underwriters. PhaseBio's pre-IPO backers included New Enterprise Associates, Hatteras Venture Partners, Johnson & Johnson and Fletcher Spaght Ventures.
- VC-based PhaseBio sets IPO pricing terms
PhaseBio Pharmaceuticals Inc, a developer of new treatments for orphan diseases, has priced its IPO Of 5 million shares between $12 and $14 per share. PhaseBio will trade the stock on the NASDAQ under the ticker symbol “PHAS.” Citigroup, Cowen and Stifel are the lead underwriters. PhaseBio's backers include Rock Springs Capital, Johnson & Johnson Innovation - JJDC, Mountain Group Capital, Cormorant Asset Management, Hatteras Venture Partners and New Enterprise Associates, according to Crunchbase.
- Biotech research firm Orig3n picks up Series B funding
Boston-based Orig3n, a biotech research company focused on genetics and regenerative medicine, has secured Series B funding, raising a total of over $50 million to date since the firm's inception in 2014. Haitong International was the lead investor. Other investors that participated in the round included Hatteras Venture Partners, Alexandria Venture Investments, Labcorp, Spectrum Health Ventures, 180 degree capital, VECTR Ventures, KTB Ventures, DEFTA Partners, MMIC Investment Holdings and Mountain Group Partners.
- StrideBio grabs $15.7 mln Series A
Durham, North Carolina-based StrideBio Inc, a developer of novel AAV vectors for in vivo gene therapies, has raised $15.7 million in Series A funding. Hatteras Venture Partners led the round with participation from other investors that included Takeda Ventures Inc, UCB Ventures and Alexandria Venture Investments LLC. In addition to the funding, Dr. Jayson Punwani, a partner at Takeda Ventures Inc. and Dr. Erica Whittaker, vice president and head of UCB Ventures, have joined StrideBio's board of directors.